Anupam Rasayan to Acquire up to 74.20% of Bliss GVS Pharma for ₹1369.5 Crore
Anupam Rasayan will acquire up to 74.20% of Bliss GVS Pharma for up to ₹1369.51 crore via share purchase and an open offer. The acquisition aims to integrate pharmaceutical value chains. Bliss GVS Pharma reported ₹1000.64 crore turnover as of March 31, 2026. The transaction is expected within 6 months.
The acquisition involves a substantial financial outlay and aims to significantly expand the company's operational scope and market presence within the pharmaceutical sector. This strategic move is expected to have a material impact on Anupam Rasayan's business and financial performance.
The acquisition of a significant stake in Bliss GVS Pharma is a strategic move that is expected to strengthen Anupam Rasayan's position in the pharmaceutical value chain, leading to enhanced integration and diversification. This is generally viewed as a positive development for growth and value creation.
Anupam Rasayan (India) Limited announced today, May 23, 2026, that its board of directors has approved a significant acquisition of equity shares in Bliss GVS Pharma Limited. The company proposes to acquire up to 74.20% of the total paid-up share capital and control of Bliss GVS Pharma, a publicly listed pharmaceutical company.
The acquisition will occur through two primary avenues. Firstly, Anupam Rasayan will purchase up to 4,58,03,024 equity shares, representing 43.30% of Bliss GVS Pharma's capital, from identified sellers at a price of ₹299 per share. This initial transaction, subject to a share purchase agreement (SPA), is valued at up to ₹1369.51 crore.
Additionally, Anupam Rasayan has the option to acquire further shares. This includes up to 4.90% of the equity share capital (Option Shares) at the SPA price on the closing date, and subsequently, any retained shares within a specified timeframe and at prevailing market prices, or ₹299 per share if the market price is lower.
Secondly, Anupam Rasayan will make an open offer to the public shareholders of Bliss GVS Pharma to acquire up to 26% of the total paid-up equity share capital at ₹299 per share, aggregating up to ₹829.03 crore. This open offer will be conducted in accordance with SEBI's substantial acquisition regulations.
The company also has the consent to acquire between 15% to 100% of the issued and paid-up equity share capital of other identified entities to facilitate this proposed transaction. The board meeting commenced at 12:45 p.m. IST and concluded at 04:55 p.m. IST on May 23, 2026.
Bliss GVS Pharma, incorporated in 1984, is engaged in manufacturing pharmaceutical products and reported a consolidated turnover of ₹1000.64 crore and a net worth of ₹1231.76 crore as of March 31, 2026. The acquisition is expected to strategically strengthen Anupam Rasayan's presence across the pharmaceutical value chain, creating an integrated and diversified manufacturing platform. The SPA is expected to be completed within 6 months.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.